Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.
- DOI
- 10.1007/s40259-026-00799-5
- Published
- 2026 Sep
- Container
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s40259-026-00799-5,
title = {Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.},
author = {Roccatello D and Sciascia S and Rossi D and Fenoglio R},
year = {2026},
journal = {BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy},
doi = {10.1007/s40259-026-00799-5},
url = {https://doi.org/10.1007/s40259-026-00799-5}
}RIS
TY - JOUR TI - Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape. AU - Roccatello D AU - Sciascia S AU - Rossi D AU - Fenoglio R PY - 2026 JO - BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy DO - 10.1007/s40259-026-00799-5 UR - https://doi.org/10.1007/s40259-026-00799-5 ER -
APA
D, R., S, S., D, R., & R, F. (2026). Targeting CD38 Across Autoimmune and Plasma Cell-Driven Immune-Mediated Diseases: Rationale, Clinical Evidence, and Emerging Therapeutic Landscape.. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. https://doi.org/10.1007/s40259-026-00799-5
Source records
- pubmed · retrieved 2026-09-25T01:09:09.880Z